REVIEW PAPER
Rheumatoid arthritis and urinary tract infections
Online publication date: 2011-12-28
Reumatologia 2011;49(6):426-431
KEYWORDS
ABSTRACT
The risk of development of urinary tract infections (UTI) in patients (pts) with rheumatoid arthritis (RA) is higher as compared with controls. In the article, based on the recent references, the relationship between RA and UTI is analyzed (Table I). The main causes of the increased rate of UTI in RA pts are: immunological disturbances and treatment with non-biologic and biologic agents. UTI in RA pts significantly increase the risk of death. The new hypothesis about the upper urinary tract infection by Proteus mirabilis as a cause of RA is also discussed. Early diagnosis of UTI in RA pts and anti-urinary tract infection specific management are extremely important for the long-term prognosis in RA.
REFERENCES (31)
1.
Kucharz EJ. Reumatoidalne zapalenie stawów. W: Wielka interna – reumatologia. Puszczewicz M (red.). Medical Tribune Polska, Warszawa 2010; 75-88. .
2.
Duława J. Zakażenia układu moczowego. W: Wielka interna – nefrologia. Myśliwiec M (red.). Medical Tribune Polska, Warszawa 2009; 330-342. .
3.
Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-2293. .
4.
Lewandowski B, Kita K, Tytman K i wsp. Patologia układu moczowego w reumatoidalnym zapaleniu stawów. Reumatologia 1992; 30: 95-103. .
5.
Luzi G, Lagana` B, Salemi S, Di Rosa R. Are glucocortycosteroids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept? Clin Ter 2009; 160: 121-123. .
6.
Weisman MH, Paulus HE, Burch FX, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 2007; 46: 1122-1125. .
7.
van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53: 224-228. .
8.
Hughes LB, Criswell LA, Beasley TM, et al. Genetic risk factors for infections in patients with early rheumatoid arthritis. Genes Immun 2004; 5: 641-647. .
9.
Koivuniemi R, Leirisalo-Repo M, Suomalainen R, et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol 2006; 35: 273-276. .
10.
Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, Proteus, anti-CCP antibodies and Karl Popper. Autoimmun Rev 2010; 9: 216-223. .
11.
Ebringer A, Rashid T. Rheumatoid arthritis is an autoimmune disease triggered by Proteus urinary tract infection. Clin Dev Immunol 2006; 13: 41-48. .
12.
Rashid T, Tiwana H, Wilson C, Ebringer A. Rheumatoid arthritis as an disease caused by Proteus urinary tract infections: a proposal for a therapeutic protocol. Isr Med Assoc J 2001; 3: 675-680. .
13.
Filipowicz-Sosnowska A. Rola infekcji w indukcji amyloidozy w przebiegu reumatoidalnego zapalenia stawów. Reumatologia 1983; 21: 311-315. .
14.
Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-494. .
15.
Nolewajka-Lasak I, Nolewajka E, Ziółkowski G, Król W. Zakażenia układu moczowego u chorych na reumatoidalne zapalenie stawów. Reumatologia 2004; 42: 447-452. .
16.
Lewandowski B, Zdrodowska-Stefanow B, Bernacka K i wsp. Występowanie zakażeń Chlamydia trachomatis w reumatoidalnym zapaleniu stawów. Reumatologia 1992; 30: 11-14. .
17.
Doran MF, Crowson CS, Pond GR, et al. Predictors of infections in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-2300. .
18.
Tishler M, Caspi D, Almog Y, et al. Increased incidence of urinary tract infection in patients with rheumatoid arthritis and secondary Sjögren’s syndrome. Ann Rheum Dis 1992; 51: 604-606. .
19.
Kita K, Bernacka K, Pietruczuk M. Obraz kliniczny i immunologiczny reumatoidalnego zapalenia stawów powikłanego zakażeniem układu moczowego. Reumatologia 1992; 30: 175-181. .
20.
Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risk in the elderly. Rheumatology 2011; 50: 124-131. .
21.
Caporali R, Caporali M, Babbio-Pallavicini F, et al. DMARDS and infections in rheumatoid arthritis. Autoimm Rev 2008; 8: 139-143. .
22.
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46: 1157-1160. .
23.
Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systemic literature research. Ann Rheum Dis 2009; 68: 1100-1104. .
24.
Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modyfying antirheumatic drugs and risk of infection in patient with rheumatoid arthritis. Arthritis Rheum 2008; 59: 1074-1081. .
25.
Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-346. .
26.
Askling J, Dixon W. The safety of anti-tumor necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 138-144. .
27.
Covelli M, Sarzi-Puttini P, Atzeni F, et al. Safety of rituximab in rheumatoid arthritis. Reumatismo 2010; 62: 101-106. .
28.
Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002; 61: 358-361. .
29.
Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumor necrosis factor blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007; 46: 327-334. .
30.
Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412. .
31.
Filipowicz-Sosnowska A. Terapie biologiczne w leczeniu reumatoidalnego zapalenia stawów. Terapia 2003; 10: 143.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
